LAUSR

Aims: The purpose of this study was to compare the effect of naringin 100 mg/kg in combination with pravastatin 10 mg/kg by gavage for 6 weeks compared with monotherapy over lipid profiles, glucose levels and weight in murine model of obesity. Main methods: The study design was planned with 5 groups of 6 male Wistar Albina rats: Group 1: control with balanced food and vehicle (C−); Group 2: control with Obesity and vehicle (C+); Group 3: Obesity + naringin (N); Group 4: Obesity + pravastatin (P); Group 5: Obesity + pravastatin + naringin (NP). Obesity was developed with a food model. Key findings: The naringin groups showed a decrease in weight gain and low glucose values compared to the control group (weight NP:311.4 vs C+:348.6; glucose NP: 173.12 vs C+:235.56) (p < 0.05); the group with naringin + pravastatin combination showed the total cholesterol (TC), LDL and triglycerides (TGs) to normal levels (TC NP:51.6 vs C+:83.4; LDL NP:9.32 vs C+:32.32; TGs NP:39.4 vs C+:89.4) (p < 0.05); but was not statistically significant compared with monotherapy. Significance: The combination of naringin and pravastatin did not appear to be better than monotherapy on lipids, but its use could generate euglycemic and antiobesogenic effects, in addition to diminishing the adverse hepatic effects of pravastatin in rats.